Aptose Biosciences acquired by Hanmi Pharmaceutical for C$2.41/share; deal closed

Aptose Biosciences Inc.

Aptose shareholders receive C$2.41 per share, a 28% premium over 30-day VWAP of C$1.88.
Acquisition by Hanmi Pharmaceutical closed; all outstanding shares not owned by Hanmi acquired.
Shareholder and court approvals obtained on March 31, 2026; Korean regulatory approvals received.
Common shares to be delisted from TSX on or about July 3, 2026; company to cease public reporting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.